Drug Discovery

£56m medicines manufacturing innovation center to be established in Scotland

A new £56m medicines manufacturing innovation center (MMIC) is to be established in Renfrewshire, Scotland, to offer businesses support to transform processes and technologies.

NeuroVive grants LHON therapy license to BridgeBio Pharma

NeuroVive Pharmaceutical has granted exclusive license of a subset of succinate prodrug chemistry under its NVP015 program to BridgeBio Pharma.

Sage, Shionogi to collaborate on MDD drug in three Asian countries

Sage Therapeutics and Shionogi & Co. have agreed to collaborate for the clinical development and commercialization of the former’s SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea.

BridgeBio Pharma to acquire late stage therapy for ultra-rare disorder from Alexion

BridgeBio Pharma has entered into an agreement with Alexion Pharmaceuticals to acquire cyclic pyranopterin monophosphate (cPMP; ALXN1101), a synthetic enzyme co-factor therapy for patients with the ultra-rare disease caused by molybdenum cofactor deficiency (MoCD) Type A.

Sanofi Pasteur to buy license of Translate’s mRNA technology in $805m deal

Sanofi Pasteur, the vaccines business of French pharma firm Sanofi, has agreed to acquire exclusive license of Translate Bio’s mRNA technology to develop messenger RNA (mRNA) vaccines in a deal that could be worth up to $805m.

Oncologie commences operations in Boston and Shanghai

Oncologie is launching operations in both Boston and Shanghai with $16.5m seed financing led by Pivotal bioVenture Partners China.

Sirnaomics secures $25m to expand clinical programs of anti-fibrosis and anti-cancer RNAi therapeutics

Sirnaomics, a biopharmaceutical company in development of RNAi therapeutics, has closed Series C1 financing of $25m.

Pfizer to invest $600m in biotechnology and other growth companies

Pfizer said that it will invest $600m in biotechnology and other emerging growth firms through its venture capital arm Pfizer Ventures for the development of life-changing therapies to patients in need.

Nimbus Therapeutics raises $65m in new capital to expand discovery efforts

Nimbus Therapeutics has raised $65m in new capital to accelerate its pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, oncology and metabolic disease.